OmniAb, Inc.

NASDAQ:OABI

Biotechnology

Healthcare
$5.08 +7.88%

+$0.16 today

Market cap
$740.97M
Beta
1.15
P/E (TTM)
-5.2
EPS (TTM)
-$0.42
52W Low $1.30High $2.79

Volume 1.22M

Average 0.67M

OABI Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

OmniAb, Inc.NASDAQ: OABI

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $3.34M fell 19.4% year over year, ahead of the -24.7% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 7.4% from the prior quarter. Over 3 fiscal years it compounded at -4.8% a year.

Context

  • Stock-based compensation amounted to 84.8% of revenue in FY2025, up 3.3 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -19.4% holds above the trailing-twelve-month pace of -24.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.34M-7.4% QoQ
Last fiscal yearDec 2025
$15.82M-26.4% YoY
LTMMar 2026
$15.02M-24.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-19.4%——
1 year-26.4%——
3-year CAGR-4.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
15.82M USD
Year-over-year change
-26.4%
4-year CAGR
+1.2%

Stock-Based Compensation vs competitors

How OABI compares with its peers on the latest reported figures

  • OABI's LTM Mar 2026 stock-based compensation of $15.02M is the largest of the 4 companies compared; the peer median is $12.55M.
  • Its year-over-year change of -24.7% is the 2nd highest of 4, against a peer median of -55.6%.
  • Stock-based compensation amounts to 52.0% of revenue for OABI, versus a peer median of 10.1%.
OABI Competitors Peer median
Stock-Based Compensation for OABI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OABIOmniAb, Inc.LTM Mar 2026$15.02M -24.7%-4.8%52.0%
ABSIAbsci CorporationLTM Mar 2026$13.53M -11.4%+13.5%737.0%
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M -55.6%-11.3%8.0%
STROSutro Biopharma, Inc.LTM Mar 2026$10.03M -58.5%-18.9%10.1%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding OABI) $12.55M-55.6%-11.3%10.1%

Competitors are the stored peer set for OABI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.04M)(22.33M)(50.62M)(62.03M)(64.78M)
Depreciation & Amortization16.25M18.25M19.5M23.58M21.75M
Deferred Income Tax(7.33M)(6.42M)(12.54M)(9.04M)(1.53M)
Stock-Based Compensation15.07M18.32M24.82M21.5M15.82M
Change in Working Capital(2.63M)(10.83M)24.87M(10.17M)(4.95M)
Accounts Receivables6.02M(12.74M)26.9M(625K)189K
Inventory(1.51M)0000
Accounts Payables1.51M15.07M920K(2.41M)(231K)
Other Working Capital(8.65M)(13.16M)(2.95M)(7.14M)(4.91M)
Other Non-Cash Items9K(572K)(3.68M)(3.5M)(4.3M)
Operating Cash Flow(5.67M)(3.59M)2.35M(39.66M)(36.46M)
Capital Expenditures(4.07M)(17.17M)(1.64M)(1.88M)(565K)
Acquisitions (Net)00000
Purchases of Investments0(54.78M)(112.62M)(40.29M)(46.86M)
Sales of Investments1.27M70K100.32M80.45M50.89M
Other Investing Activities(1.22M)(1.44M)(4.44M)(400K)3M
Investing Cash Flow(4.03M)(73.31M)(18.38M)37.88M6.47M
Debt Repayment00000
Common Stock Issued096.24M011.37M28.36M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.7M14.5M(892K)1.65M(450K)
Financing Cash Flow9.7M110.74M(892K)13.02M27.91M
Effect of Forex Changes00000
Net Change in Cash033.84M(16.92M)11.24M(2.07M)
Free Cash Flow(9.74M)(20.76M)703K(41.54M)(37.02M)

OmniAb, Inc.

NASDAQ:OABI

Intrinsic Alpha fair value

Locked

Current Price

$5.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.